Looking at him now, our blue-eyed, funny, fearless little boy, Tom, it was all worth it. Every what if, every tear shed, ...
Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback